CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

宮崎市, Japan

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits

    This pilot study employs a pre-post, open trial design with the primary aim to investigate the feasibility of delivering parenting educational materials in an accessible format, i.e., a widely used testing platform. The training videos demonstrate the applications of antecedent- and reinforcement-based behavior management techniques in a specific situation and encourage parents to build positive parenting habits. The program usability and satisfaction will be assessed through participant ratings. The study targets parents of children demonstrating inattention, hyperactive, and impulsive behavior. These families frequently experience difficulties managing everyday routines at home, yet the access to psychosocial treatment is limited. The investigators expect parents to engage well in the program delivered via digital media. Based on the existing literature on the effectiveness of behavior parent training delivered in traditional in-person format, a moderate effect size is expected in the pre-post measures of parenting practices and the child target behavior for this study.

    Phase

    N/A

    Span

    61 weeks

    Sponsor

    Okinawa Institute of Science and Technology Graduate University

    Miyazaki

    Recruiting

    Healthy Volunteers

  • A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

    Phase

    3

    Span

    265 weeks

    Sponsor

    Eli Lilly and Company

    Miyazaki

    Recruiting

  • A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

    Phase

    1/2

    Span

    360 weeks

    Sponsor

    Bristol-Myers Squibb

    Miyazaki

    Recruiting

  • Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan

    Phase

    N/A

    Span

    182 weeks

    Sponsor

    AbbVie

    Miyazaki

    Recruiting

  • Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets

    Phase

    N/A

    Span

    280 weeks

    Sponsor

    AbbVie

    Miyazaki

    Recruiting

  • A Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis

    Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor. Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response. Arm 3 will enroll patients who have been previously treated on JAK inhibitor (except momelotinib) that was complicated by anemia, thrombocytopenia or hematoma.

    Phase

    1/2

    Span

    542 weeks

    Sponsor

    Sumitomo Pharma America, Inc.

    Miyazaki

    Recruiting

  • Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

    This is a mandatory Post-Marketing Surveillance (PMS) requested by Pharmaceuticals and Medical Devices Agency (PMDA) as a part of the Japan-Risk Management Plan (J-RMP).

    Phase

    N/A

    Span

    331 weeks

    Sponsor

    Astellas Pharma Inc

    Miyazaki

    Recruiting

  • REASSURE-NIRS Registry

    NIRS imaging is an invasive intravascular imaging modality to quantitatively visualize lipid-rich atheroma in vivo. While NIRS-derived lipid-rich plaque has been shown to associate with cardiovascular events, there is limited clinical data about the association of this high-risk plaque with risk factors, medication use, prognosis and response of PCI. RESSURE-NIRS registry is an on-going multi-center prospective registry in Japan, which enroll subjects with coronary artery disease who received NIRS imaging to evaluate coronary atherosclerosis. The primary outcome is maximum 4-mm lipid core burden index at coronary lesions measured by NIRS imaging. Secondary major outcomes include entire lipid core burden index, plaque volume, plaque attenuation and echo-lucent area. The anticipated number of study subjects is 2000 cases.

    Phase

    N/A

    Span

    338 weeks

    Sponsor

    National Cerebral and Cardiovascular Center

    Miyazaki

    Recruiting

  • A Clinical Study of the Paradise™ Renal Denervation System in Patients with Hypertension (RADIANCE-HTN DUO)

    Phase

    N/A

    Span

    392 weeks

    Sponsor

    Otsuka Medical Devices Co., Ltd. Japan

    Miyazaki

    Recruiting

  • Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

    Phase

    3

    Span

    401 weeks

    Sponsor

    Bayer

    Miyazaki

    Recruiting

1-10 of 25
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information